Advanced Medical Solutions is involved in the manufacturing, development, and distribution of surgical and wound care products to clinicians. The leading independent innovator of global advanced wound care and surgical care reported a profit hike to £11,081m from £4,425m in 2020. As a result, return on equity and operating margins were 6.9% and 7.7%, respectively, both above the health care industry benchmark. Consequently, it implies that investors could derive higher returns on their investment in the firm, where EPS growth stands at 18.8%, above the 13.7 EPS growth from the health care industry. This evidence suggests that funds could be allocated into Advanced Medical Solutions to conduct impact investing, while optimising the value of the portfolio, since the firm delivered technologically advanced products to assist clinicians with their patients.
Keep up to date with WealthOracle AM |
We have gone past the register date of the 24 Sept, still rising good to see. Dividend paid on 22 Oct maybe time to take a little profit IMHO. |
@dealit! "Nice if we could reach £320 area upto ex-dividend."
Hit £3.20. |
Advancing nicely |
Tipped in IC this week citing recovery of elective surgery and R&D increases. |
Nice if we could reach £320 area upto ex-dividend. |
"During the Period, AMS delivered strong revenue growth, profitability and cash generation, alongside significant regulatory and clinical progress in developing the next generation of innovative products that we expect to drive further growth over the coming years. AMS is in robust financial health to deliver organic and acquisitive growth, and reflecting the confidence of the board, the interim dividend is being increased for the half year. " |
Don’t like the way they omit comparisons with pre-Covid figures. Other companies all manage it. |
Would feel share price steady increase up to dividend date IMHO. |
Nice increase in divi. |
Good results-Well done! |
Baited breath? |
Results tomorrow |
Very positive trading statement today IMHO. |
The story looks quite good here and there has been a high level of investment by the company over the past couple of years. Medical spending should increase significantly as hospitals go into catch-up mode on surgery. Balance sheet looks robust and management is said to be ok. Directors have also been buying recently so I have opened up a position this morning. |
Ah, so now we know why the sp’s been on the rise.
today’s RNS is good news. |
Aiui Rapid Liquiband was expected to get FDA approval in Q1 this year, and that should help, plus of course the very successful vaccination programme in the US which should soon increase elective surgery to normal levels. AMS could prove a tasty morsel for one of the many giant US medical companies. |
Since April 5th this is a different company - according to the sp!
;-) |
AMS are a rock solid Company with a good management team. They are waiting approval from FDA on some next generation products which IMHO will take the share price to a higher level. |
Off the radar |
As elective surgery starts to get busier as we come out of lockdown who thinks this company will start its climb back up? |
Amazing some of the six-figure trades that suddenly appear in a largely ignored stock.
Presumably just blocks being transferred at an agreed price, as the share price barely moves. |
If the trading statement is correct steady progress in difficult times. |
Plenty of volume yesterday.
Everything’s looking rosy. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
